Topic: colorectal cancer

Having failed to improve outcomes in metastatic NSCLC, the anti-CTLA4 antibody has now missed the mark in a phase 3 head and neck cancer trial.

The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.

Boehringer Ingelheim Venture Fund co-led the financing to tee Amal up to take lead colorectal cancer vaccine ATP128 into the clinic next year.

Exact Sciences announced third-quarter revenues of $118.3 million after it screened about 241,000 people with its Cologuard at-home test.

Different KRAS mutations exert diverging effects on protein function, a new study illustrates.

After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.

Pfizer signed on to co-promote Exact Sciences’ Cologuard colorectal cancer screening test, committing to about $70 million on marketing through 2021.

The CEA-CD3 bispecific T-cell engager was pitched as a treatment for colorectal cancer but looks to have failed in early-phase trials. 

Syndax’s entinostat-Keytruda combination may have posted small gains in NSCLC, but an enrichment biomarker could predict increased clinical benefit.

The startup sees the test enabling the detection of cancers and stratification of patients through the analysis of exhaled volatile organic compounds.